



SAS:sas 6235-59221-01 Document in ProLaw

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket Number	6235-59221-01
Application Number	09/869,475
Filing Date	October 10, 2001
First Named Inventor	Ryuichi Morishita
Art Unit	1635
Examiner Name	Brian Whiteman

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
DL		Kala <i>et al.</i> , "Angiogenesis und Vaskulogenes," <i>Hertz</i> 25:611-622, 2000 (English abstract)
		Li <i>et al.</i> , "Technology evaluation: gene therapy (FGF-5), Vical," <i>Curr. Opin. Molec. Therap.</i> 1:260-5, 1999
		Morishita <i>et al.</i> , "Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy," <i>Hypertension</i> 33:1379-1384, 1999
		Prud'homme and Chang, "Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon gamma receptor/IgG1 fusion protein," <i>Gene Therapy</i> 6:771-7, 1999
		Rochlitz, "Gene Therapy of Cancer," <i>Drugs of Today</i> 36:619-629, 2000
DL		Udea <i>et al.</i> , "Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart," <i>Ann. Thorac. Surg.</i> 67:1726-31, 1999.

EXAMINER SIGNATURE:	DATE CONSIDERED: 8/10/04
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	